Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients (Q42997163)

12 November 2017

Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients (English)

1 reference

12 November 2017

1 reference

Kazuhiro Hayashida

1

1 reference

12 November 2017

Akito Daiba

2

1 reference

12 November 2017

Akito Sakai

3

1 reference

12 November 2017

Takeshi Tanaka

4

1 reference

12 November 2017

Kyosuke Kaji

5

1 reference

12 November 2017

Niro Inaba

6

1 reference

12 November 2017

Satoshi Ando

7

1 reference

12 November 2017

Naoki Kajiyama

8

1 reference

12 November 2017

Hiroshi Terasaki

9

1 reference

12 November 2017

Aki Abe

10

1 reference

12 November 2017

Masanori Ogasawara

11

1 reference

12 November 2017

Michinori Kohara

12

1 reference

12 November 2017

Mine Harada

13

1 reference

12 November 2017

Takeshi Okanoue

14

1 reference

12 November 2017

Satoru Ito

15

1 reference

12 November 2017

Shuichi Kaneko

16

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Clinical Gastroenterology and Hepatology

12 November 2017

1 reference

12 November 2017

3

1 reference

12 November 2017

12

1 reference

12 November 2017

1253-1259

1 reference

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Quantitative analysis of interferon alpha/beta receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Differential gene expression between chronic hepatitis B and C hepatic lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

A low-density cDNA microarray with a unique reference RNA: pattern recognition analysis for IFN efficacy prediction to HCV as a model

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Comprehensive gene expression profile of a normal human liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900412-X

7 January 2021

10.1016/S1542-3565(05)00412-X

Identifiers

DOI

1 reference

12 November 2017

1 reference